Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P304 | DOI: 10.1530/endoabs.56.P304

1Endocrinology and Nutrition Department, Alicante University General Hospital, ISABIAL-FISABIO, Alicante, Spain; 2Miguel Hernández University, Alicante, Spain.


Introduction: PCSK9 inhibitors (iPCSK9) have previously been evaluated through controlled clinical trials showing up to 60% reduction in LDL cholesterol concentrations. However, we still do not have enough data regarding the real life experience of the treatment.

Objectives: 1) Describe patients with hypercholesterolemia treated with iPCSK9 in clinical practice.

2) Evaluate treatment efficacy and safety.

Methods: Retrospective observational study. Inclusion criteria: patients treated with iPCSK9 at the Alicante University General Hospital. Primary end point: changes in LDL cholesterol 3 and 6 months after the start of iPCSK9. Secondary end point: changes in total cholesterol (TC), HDL cholesterol and triglycerides (TG). Other variables: Occurrence of adverse events. Statistical analysis: descriptive (mean ± S.D., median [P25–P75]), Wilcoxon; P<0.05; SPSS v22.0.

Results: 24 patients (50% women, age 60±12 years, BMI 27±3 kg/m2). 62.5% heterozygous familial hypercholesterolemia, 58% onset cardiovascular disease, 21% both. At baseline 66% patients were taking combination ezetimibe-statins therapy (21% rosuvastatin 20 mg/d, 4% rosuvastatin 10 mg/d, 13% rosuvastatin 40 mg/d, 21% atorvastatin 80 mg/d), 21% statin therapy (8% rosuvastatin 20 mg/d, 8% atorvastatin 80 mg/d), 4% monotherapy with ezetimibe 10 mg/d. Evolocumab 140 mg was prescribed in 62.5% of cases and alirocumab 75 mg in 37.5%. Primary end point: 50% reduction in LDL [16–61%] at 3 months, 55% [42–74%] at 6 months (P<0.01). Secondary end point: 38% reduction in TC [21–44%] at 3 months, 41% [21–44%] at 6 months (P<0.01). Non-significant 7% decrease in TG at 3 months, 3% at 6 months. There were also no significant changes in HDL. 5 of the 24 patients (21%) presented mild adverse events: 1 recurrent respiratory tract infections, 2 flu-like syndrome, 1 hypertransaminasemia, 1 pruritus. None of them demonstrated increase in plasma glucosa levels, or showed neurocognitive symptoms.

Conclusion: In short-term real life studies, the addition of PCSK9 inhibitors to their previous treatment leads to improvement in metabolic control with an adequate safety profile.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.